STAT Plus: Loxo’s cancer drug wins a pioneering FDA approval. Now it has to find some patients
NIH
Upending regulatory tradition may have been the easy part. Now the company has to scour the world for patients with a rare genetic mutation.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario